Human capital management (HCM) and workforce management suites are evolving from consolidation tools to core infrastructure for enterprise efficiency and competitiveness, according to new research ...

HR Path, a global leader in HR consulting and HRIS solutions, is pleased to announce the strategic acquisition of Covalence Consulting Inc., a specialized HR technology consulting firm recognized for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...

NEW ORLEANS, LA—Mavacamten (Camzyos; Bristol Myers Squibb) better reduces left ventricular outflow tract (LVOT) obstruction than placebo among adolescent patients with obstructive hypertrophic ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

HCM is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of HCM shares has decreased $0.04 since the market last closed. This is a 0.25% ...

HCM is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of HCM shares has increased $0.38 since the market last closed. This is a 2.47% ...

Approved pharmacologic therapies for pediatric hypertrophic cardiomyopathy are lacking, and surgical intervention may be indicated in patients with left ventricular outflow tract obstruction. The ...

The fund invests under normal circumstances at least 80% of its assets (net assets plus the amount of any borrowings made for investment purposes) in the stocks in the index in proportion to their ...